177
Participants
Start Date
March 31, 2010
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
CAD106
150μg and 450μg doses were reconstituted and administered via intramuscular injection
Placebo
Identical placebo to CAD106 administered via intramuscular injection
Alum
An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106
MF59
An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
Novartis Investigative Site, Lausanne
Novartis Investigative Site, Antwerp
Novartis Investigative Site, Biel
Novartis Investigative Site, Leuven
Novartis Investigative Site, Basel
Novartis Investigative Site, Stavanger
Novartis Investigative Site, Genova
Novartis Investigative Site, Milan
Novartis Investigative Site, Brescia
Novartis Investigative Site, Hollywood
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Mölndal
Novartis Investigative Site, Barakaldo
Novartis Investigative Site, Florence
Novartis Investigative Site, Boulder
Novartis Investigative Site, Nuremberg
Novartis Investigative Site, Costa Mesa
Novartis Investigative Site, Indianapolis
Novartis Investigative Site, Eatontown
Novartis Investigative Site, Toronto
Novartis Investigative Site, Toronto
Novartis Investigative Site, Greenfield Park
Novartis Investigative Site, Montreal
Novartis Investigative Site, Roma
Novartis Investigative Site, Roma
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Sant Cugat del Vallès
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Stockholm
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY